BHC Intrinsic Value Calculator – BAUSCH HEALTH COMPANIES Reports Q2 FY2023 Earnings Results
August 13, 2023
🌥️Earnings Overview
For the second quarter of FY2023 ending June 30, 2023, BAUSCH HEALTH COMPANIES ($NYSE:BHC) reported total revenue of CAD 2167.0 million, a decrease of 14.5% compared to the same period in the prior year. Net income for the quarter was CAD 26.0 million, a remarkable increase of 113.9% year-on-year.
Stock Price
On Thursday, BAUSCH HEALTH COMPANIES reported their financial results for the second quarter of Fiscal Year 2023. The company’s stock opened at $9.8 and closed at $9.4, up by 0.9% from the prior closing price of $9.3. This indicates that the company was able to manage its costs and expenses efficiently. Moving forward, the company plans to continue to focus on driving long-term growth through strategic investments and acquisitions.
Overall, the second-quarter results show that BAUSCH HEALTH COMPANIES is well-positioned to capitalize on its strong momentum in the healthcare industry. The company has a solid financial platform, with a strong balance sheet, and management is confident in its ability to deliver long-term value to its shareholders. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for BHC. More…
| Total Revenues | Net Income | Net Margin |
| 11.47k | -261.54 | -1.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for BHC. More…
| Operations | Investing | Financing |
| -588.28 | -407.46 | -781.78 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for BHC. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 33.8k | 33.44k | -2.42 |
Key Ratios Snapshot
Some of the financial key ratios for BHC are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 2.1% | 9.8% | 16.1% |
| FCF Margin | ROE | ROA |
| -8.0% | -117.5% | 3.4% |
Analysis – BHC Intrinsic Value Calculator
GoodWhale has conducted an in-depth analysis of BAUSCH HEALTH COMPANIES’s wellbeing. Our proprietary Valuation Line has calculated the fair value of BAUSCH HEALTH COMPANIES share to be around $17.6. This means that presently, the stock is trading at $9.4, which is a significant 46.5% undervalued from its fair value. We believe this discrepancy presents investors with the potential to make a great return on their investments. More…
Summary
BAUSCH HEALTH COMPANIES reported strong second quarter earnings results ending June 30 2023, with total revenue of CAD 2167.0 million, a decrease of 14.5% year over year, and net income of CAD 26.0 million, a significant increase of 113.9%. This indicates a positive outlook for the company and could be a good investment opportunity for those looking to diversify their portfolio. The company has proven to be resilient in times of economic hardship and its strong performance could provide investors with potential returns. With the promising results from the second quarter, it is highly likely that investors will find BAUSCH HEALTH COMPANIES to be an attractive investment.
Related Posts
Recent Posts
